Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythem ...

Agenus Inc. , a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25?30, 2025 in Chicago, ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

在全球肿瘤免疫治疗领域，一则来自中国药企的消息正在引发行业震动。2025年3月24日，基石药业向欧洲药品管理局提交舒格利单抗治疗III期非小细胞肺癌的新适应症申请，距离其首次获批IV期肺癌适应症仅隔15个月。这个时间节点折射出的不仅是单一药物的研发进程，更揭示了中国生物医药产业正在经历的战略跃迁。弗若斯特沙利文数据显示，全球III期NSCLC患者群体约占总肺癌患者的28%，其中约40%因缺乏有效巩 ...

Zenas’ lead product candidate, obeelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, which are broadly present across B cell lineage ... that still exist in treating ...

Tevimbra is a humanised immunoglobulin G 4 (IgG4) anti-programmed cell death protein ... The antibody is engineered to decrease the interaction with Fc-gamma receptors on macrophages.

Tevimbra is a humanised immunoglobulin G 4 (IgG4) anti-programmed cell death protein 1 (PD-1 ... The antibody is engineered to decrease the interaction with Fc-gamma receptors on macrophages. It has ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death ... It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping the ...

趁国际罕见病日的契机，我们将带大家陆续认识下风湿病中的罕见病。 今天为大家介绍的是 IgG4相关性疾病(IgG4-Related Disease, IgG4-RD)。IgG4-RD是一种自身免疫性疾病，表现为多脏器肿大和功能异常、血清IgG4水平升高。该疾病在2010年才真正作为一种综合征正式命名。

为探究新冠 mRNA 疫苗接种后 IgG4 对 Fc 介导反应的影响，墨尔本大学研究人员开展研究，发现 IgG4 对 Fc 功能影响取决于多种因素，这对理解疫苗免疫机制有重要意义。 在新冠疫情这场全球公共卫生危机中，新冠疫苗成为人们抗击病毒的有力武器。新冠 mRNA 疫苗 ...

TEVIMBRA ® (tislelizumab) is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell ... it is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages ...